Telesta Therapeutics Inc. (BNC)

[BioSpecialist]

Signs of big Phase3 Success

BIG PAYDAY IS COMING FOR BNC SHAREHOLDERS .I LOVE IT .

MAKRET CAP OF 100 MILLION$ IS WAYYYYY UNDERVALUED .


1) Chief Medical Officer exercise his options for ~ 130.000 C$

Sep 20/10 Sep 20/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 50,000 $1.100

Sep 20/10 Sep 16/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 80,000
.900

...........

2) Urocidin (Bladder Cancer) Phase 3 is a small Studie with 105 Patients,only "20% complete response” required for Phase 3 success .

Previous Positive Phase 2 Results Involving 128 Patients :

We have a 70% complete response rate in patients who failed othertherapies, so our Phase II data, which is in the public domain, showsabout 128 patients with an average complete response of about 70%.

..........

3) Complete all DMC ( Data Monitoring Committees) Meetings POSITIV :

Since commencement, nine meetings of the independent DMC have recommended to “continue the trial unmodified”

The DMCis an independent group that acts in an advisory capacity to the Company.Its role is to evaluate the progress of the clinical trial,includingmonitoring the safety and efficacy data generated in thetrial.

..........

4) 21 New Employees since Feb 2010 up from 190 to 211 Personnel :

September 10,
The fully-integrated company employs 211 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety

10/02/10
The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety.

..........

5) Positive Comments by CEO , BladderCancer Forum and Alvaro Morales ( Father of BCG )

CEO Graeme McRae
http://www.quintenews.com/2010/09/banner-year-for-bellevilles-bioniche/

Shareholders will be really happy in two to three years when productionof the bladder cancer drug starts to roll onto the market.


BladderCancer Forum (4 months ago)
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862

I can tell you that the people I know at Bioniche are extremely positive about their product.


Alvaro Morales
http://community.advanceweb.com/blogs/al_1/archive/2009/07/13/an-immunotherapy-success-story-bcg-and-bladder-cancer.aspx

Dr Morales, professor of urology and oncologyat Queen’s University, Kingston, Ont., and principal investigator ofthe trial: “My own experience sugg­ests very stronglythat the safety profile of MCC is much better than BCG and,certainly, MCC iseasier to handle, from the pharmacist’s,nurse’s and physician’s points ofview,due to the risk of ac­quiring a serious infection fromimproper handling o fBCG,which is a live bacteria,as opposed to MCC thatcontains only bacterial cell wall fragments and DNA.”Dr. Morales is editorof The Chronicle of Urology &Sexual Medicine.


........

6) Early (5 months) Exercise of option to take the World Wide Rights for Urocidin by Endo Pharma !

http://www.biospace.com/news_story.aspx?NewsEntityId=170692

Bioniche Life Sciences Inc. (BNC) Achieves Two Additional Milestones Under Licensing Agreement; Endo Pharmaceuticals (ENDP) Takes up Global Rights; Bioniche to Get $8 Million
2/12/2010


-----------------------------------------------------------------------------------------------------------------------------------------------------------


More Information about Bioniche :

http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=BNC&t=LIST&m=28632016&l=0&pd=0&r=0